

Financial news for SLXP dated on 2017-03-30: Bill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco

Financial news for SLXP dated on 2016-03-17: BMO Still Believes Valeant Is Undervalued

Financial news for SLXP dated on 2015-04-02: Benzinga's Volume Movers

Financial news for SLXP dated on 2015-04-01: US Stock Futures Edge Lower Ahead Of ADP Report

Financial news for SLXP dated on 2015-04-01: Valeant Completes Tender Offer for Salix Pharmaceuticals

Financial news for SLXP dated on 2015-03-24: Option Alert: Salix Apr \$175 Call; 3000 Contract Trade at Ask @\$0.10

Financial news for SLXP dated on 2015-03-18: Jefferies Downgrades Salix Pharmaceuticals As Raised Bid By Valeant Appears Final

Financial news for SLXP dated on 2015-03-18: Benzinga's Top Downgrades

Financial news for SLXP dated on 2015-03-18: Jefferies Downgrades Salix Pharmaceuticals To Hold

Financial news for SLXP dated on 2015-03-18: Jefferies Downgrades Salix Pharmaceuticals to Hold, Raises PT to \$173.00

Financial news for SLXP dated on 2015-03-16: Benzinga's M&A Chatter for Monday March 16, 2015

Financial news for SLXP dated on 2015-03-16: Bill Ackman to Buy 3M Shares In Valeant's \$1.45B Share Offering at Cost of ~\$600M -FT

Financial news for SLXP dated on 2015-03-16: FTC Has Approved Valeant, Salix Deal

Financial news for SLXP dated on 2015-03-16: Benzinga's Volume Movers

Financial news for SLXP dated on 2015-03-16: Morning Market Gainers

Financial news for SLXP dated on 2015-03-16: Endo Announces Withdrawal of Bid for Salix

Financial news for SLXP dated on 2015-03-16: Valeant Raises Salix Bid, Agree To All-Cash Deal

Financial news for SLXP dated on 2015-03-16: Benzinga's Top #PreMarket Gainers

Financial news for SLXP dated on 2015-03-16: Shares of Salix Pharma to Resume Trade at 8:30 a.m. EDT

Financial news for SLXP dated on 2015-03-16: Valeant, Salix Agree on Amended \$173/Share in Cash Deal; Raised from \$158/Share

Financial news for SLXP dated on 2015-03-16: WSJ Breaking News Tweets: 'Valeant and Salix agree to cash deal valuing Salix \$173 per share'

Financial news for SLXP dated on 2015-03-16: Hearing Valeant Has Increased Bid for Salix to \$173/Share

Financial news for SLXP dated on 2015-03-16: Salix Shares Halted News Pending

Financial news for SLXP dated on 2015-03-16: Must Watch Stocks for March 16, 2015

Financial news for SLXP dated on 2015-03-15: Benzinga's Weekend M&A Chatter

Financial news for SLXP dated on 2015-03-15: Endo Says it Can Close Salix Acquisition in as Little as Five Weeks Following Negotiated Deal, According to Email -Reuters

Financial news for SLXP dated on 2015-03-13: Valeant Announces HSR Clearance for Salix Purchase

Financial news for SLXP dated on 2015-03-13: Valeant Reportedly Planning To Raise Bid For Salix; Working With Pershing Square & ValueAct Capital To Finance Offer

Financial news for SLXP dated on 2015-03-13: UPDATE: NY Times Reports Valeant to Raise Bid for Salix

Financial news for SLXP dated on 2015-03-13: UPDATE: Spike in Valeant May be

Attributed to Value Walk Report: 'Why Valeant Could Match And Beat Endo's Offer To Buy Salix'

Financial news for SLXP dated on 2015-03-12: At Barclays Event: ENDO CEO Eyes Other Possible Opportunities If Salix Deal Falls Apart

Financial news for SLXP dated on 2015-03-12: Why Valeant, Not Endo, Could Still Win The War For Salix

Financial news for SLXP dated on 2015-03-12: William Blair Says Cash Is King In Salix Bidding War

Financial news for SLXP dated on 2015-03-12: Books on Valeant's \$9.6B High Yield Bond Near \$29B, According to Source -Reuters

Financial news for SLXP dated on 2015-03-12: Option Alert: Salix Apr \$170 Call; 1000 Contract Trade between Bid/Ask @\$3.70

Financial news for SLXP dated on 2015-03-11: Benzinga's M&A Chatter for Wednesday March 11, 2015

Financial news for SLXP dated on 2015-03-11: Valeant Committed to All-Cash Salix Transaction

Financial news for SLXP dated on 2015-03-11: Salix Confirms Receipt Of Unsolicited Proposal From Endo; Will Review & Consider

Financial news for SLXP dated on 2015-03-11: Salix Pharma To Resume Trading At 3:20PM

Financial news for SLXP dated on 2015-03-11: ENDO Sends Salix Non-Binding Proposal Letter

Financial news for SLXP dated on 2015-03-11: UPDATE: Terms For Endo Deal For Salix Consists Of 1.4607 ENDP Shares And \$45/Share Cash

Financial news for SLXP dated on 2015-03-11: Endo Sees Deal Completion With Salix By Q2 2015

Financial news for SLXP dated on 2015-03-11: UPDATE: Endo Deal To Be A Combination Of Cash & Stock

Financial news for SLXP dated on 2015-03-11: Endo Confirms Proposal To Acquire Salix For \$175/Share

Financial news for SLXP dated on 2015-03-11: Hearing Faber Says Endo/Salix Offer Has \$350M Breakup Fee

Financial news for SLXP dated on 2015-03-11: DAVID FABER @davidfaber Tweet: ENDO bid is above \$165 for \$SLXP. Sorry if said otherwise on air. Will be 25% in cash. Will require \$ENDP shareholder vote. Close late June.

Financial news for SLXP dated on 2015-03-11: CNBC's David Faber Tweets: 'ENDO bid is above \$165 for \$SLXP. Sorry if said otherwise on air. Will be 25% in cash. Will require \$ENDP shareholder vote. Close late June.'

Financial news for SLXP dated on 2015-03-11: ENDO Said To Plan On Making Salix Offer As Soon As Today

Financial news for SLXP dated on 2015-03-11: Salix Shares Halted, News Pending

Financial news for SLXP dated on 2015-03-11: Bloomberg Now Reporting ENDO will Make Bid To Salix In \$170-\$175 Range

Financial news for SLXP dated on 2015-03-11: Endo Bidding \$170/Share For Salix

Financial news for SLXP dated on 2015-03-11: Valeant to Continue With \$9.6B Bond Offering Despite Rumored Endo Bid for Salix, According to Source

Financial news for SLXP dated on 2015-03-11: Endo Sent E-Mail To Salix Offering \$165/Share

Financial news for SLXP dated on 2015-03-11: UPDATE: Endo Reportedly Bidding More than \$165/Share for Salix

Financial news for SLXP dated on 2015-03-11: UPDATE: WSJ's Deals Editor Jamie Heller Tweets: 'WSJ scoop: Endo makes takeover offer for Salix, seeking to wrest company from Valeant. \$ENDP \$SLXP \$VRX'

Financial news for SLXP dated on 2015-03-11: Endo Makes Takeover Offer For Salix,

Accoring to Sources -WSJ

Financial news for SLXP dated on 2015-03-02: Salix Pharma Reports Q4 Adj. Loss of \$2.61/Share vs Loss of \$0.25/Share Est.

Financial news for SLXP dated on 2015-03-02: Salix Reports Q4 EPS -\$4.51 Vs -\$0.25 Vs May Not Compare, Sales \$13.5M

Financial news for SLXP dated on 2015-03-02: Must Watch Stocks for Today

Financial news for SLXP dated on 2015-03-02: Earnings Scheduled For March 2, 2015

Financial news for SLXP dated on 2015-02-25: Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target

Financial news for SLXP dated on 2015-02-25: Actavis Shares Higher in Premarket as Co Confirms ANDA Filing to FDA for Generic Version of Salix' Uceris

Financial news for SLXP dated on 2015-02-24: Valeant Pharmaceuticals Is Kicking Butt, Says Canaccord Genuity

Financial news for SLXP dated on 2015-02-24: Firms Bullish On Valeant Following Earnings, Acquisition

Financial news for SLXP dated on 2015-02-24: Benzinga's Top Downgrades

Financial news for SLXP dated on 2015-02-24: UBS Downgrades Salix Pharmaceuticals To Neutral

Financial news for SLXP dated on 2015-02-24: Cantor Fitzgerald Downgrades Salix Pharmaceuticals to Hold

Financial news for SLXP dated on 2015-02-24: UBS Downgrades Salix Pharmaceuticals to Neutral, Raises PT to \$158.00

Financial news for SLXP dated on 2015-02-23: 4 Pictures Every Valeant-Salix Investor Should See

Financial news for SLXP dated on 2015-02-23: Biotech Stocks Moving Higher

Financial news for SLXP dated on 2015-02-23: Fast Money Halftime Report Final Trade From February 23

Financial news for SLXP dated on 2015-02-23: JMP Securities Comments On Salix Pharmaceutical's Takeover Valuation

Financial news for SLXP dated on 2015-02-23: Valeant CEO Explains Why The Company Is Acquiring Salix For \$10.1 Billion Cash Instead Of An Equity Offering

Financial news for SLXP dated on 2015-02-23: Cramer: Valeant's Stock Doesn't Stop Here, It Goes Higher

Financial news for SLXP dated on 2015-02-23: Benzinga's Volume Movers

Financial news for SLXP dated on 2015-02-23: Valeant Crosses Above \$200/Share Following Salix Bid

Financial news for SLXP dated on 2015-02-23: Morning Market Gainers

Financial news for SLXP dated on 2015-02-23: Piper Jaffray Downgrades Salix Pharmaceuticals To Neutral

Financial news for SLXP dated on 2015-02-23: Benzinga's Top Downgrades

Financial news for SLXP dated on 2015-02-23: Leerink Swann Downgrades Salix Pharmaceuticals to Market Perform

Financial news for SLXP dated on 2015-02-23: US Stock Futures Slip Ahead Of Economic Data

Financial news for SLXP dated on 2015-02-23: Piper Jaffray Downgrades Salix Pharmaceuticals to Neutral, Lowers PT to \$158.00

Financial news for SLXP dated on 2015-02-23: Shire Declines Comment on Potential Bid for Salix Pharmaceuticals

Financial news for SLXP dated on 2015-02-23: Must Watch Stocks for Today

Financial news for SLXP dated on 2015-02-22: Fast Money Halftime Report Final Trade

From February 20

Financial news for SLXP dated on 2015-02-22: Benzinga's Weekend M&A Chatter

Financial news for SLXP dated on 2015-02-22: Valeant to Acquire Salix Pharmaceuticals for \$158.00/Share in Cash

Financial news for SLXP dated on 2015-02-21: Valeant Near Deal to Acquire Salix for ~\$10B, According to Sources -DJ

Financial news for SLXP dated on 2015-02-21: DAVID FABER @davidfaber Tweet: Valeant deal to acquire Salix Pharma is done-sources. "Roughly" \$160 all cash. Announcement tomorrow or Monday. \$SLXP, \$VRX

Financial news for SLXP dated on 2015-02-21: Valeant Said to Agree to Buy Salix for \$158/Share in Cash -Bloomberg

Financial news for SLXP dated on 2015-02-20: Valeant Pharmaceuticals Close to Deal for Salix Pharmaceuticals -CNBC

Financial news for SLXP dated on 2015-02-18: Paulson & Company's Q4 Moves: Healthcare And Beyond

Financial news for SLXP dated on 2015-02-16: Benzinga's Weekend M&A Chatter

Financial news for SLXP dated on 2015-02-13: Endo Has Expressed Interest in Salix Pharmaceuticals, According to Source -Reuters

Financial news for SLXP dated on 2015-02-13: Sterne Agee Dives Deep Into 3 Biotechs

Financial news for SLXP dated on 2015-02-12: Benzinga's M&A Chatter for Thursday February 12, 2015

Financial news for SLXP dated on 2015-02-12: Shire Preparing Bid for Salix Pharmaceuticals, According to Sources -Reuters

Financial news for SLXP dated on 2015-02-12: Valeant Declines Comment on Report of Potential Bid for Salix

Financial news for SLXP dated on 2015-02-12: UPDATE: Bloomberg Suggesting Salix Could Draw Offers from Other Suitors

Financial news for SLXP dated on 2015-02-12: Hearing Valeant Considering Offer Over \$150/Share for Salix

Financial news for SLXP dated on 2015-02-12: Salix Spikes Higher

Financial news for SLXP dated on 2015-02-03: Benzinga's M&A Chatter for Tuesday February 3, 2015

Financial news for SLXP dated on 2015-02-03: Valeant Could Be Interested In Buying Salix; Sterne Agree Says This Makes Sense

Financial news for SLXP dated on 2015-02-03: Valeant Declines Comment on Rumor of Potential Bid for Salix

Financial news for SLXP dated on 2015-02-03: 'Valeant Pharmaceuticals International Inc. exploring Salix Pharmaceuticals Ltd takeover: sources'

Financial news for SLXP dated on 2015-02-03: Shares of Salix Pharma Trading Back To HOD On Takeover Chatter

Financial news for SLXP dated on 2015-02-03: Salix Shares Resume Now up ~4%

Financial news for SLXP dated on 2015-02-03: UPDATE: Shire Also Said To Be Amongst Companies Interested In Salix

Financial news for SLXP dated on 2015-02-03: Valeant Said To Explore Takeover Of Salix Pharma

Financial news for SLXP dated on 2015-02-03: SLXP Shares Halted On Volatility Breaker

Financial news for SLXP dated on 2015-02-03: Napo Files Brief on Appeal in Dispute With Salix Pharmaceuticals- Reuters

Financial news for SLXP dated on 2015-02-02: Salix Pharmaceuticals Santarus Unit, Cosmo Technologies Commenced Lawsuit Against Generic Drug Maker Par Pharmaceutical

Financial news for SLXP dated on 2015-02-02: Salix Announces Names William P. Forbes,

PharmD President, Medical, R&D and Chief Development Officer

Financial news for SLXP dated on 2015-01-28: Salix Provides Update on Audit Committee Review

Financial news for SLXP dated on 2015-01-20: Benzinga's M&A Chatter for Tuesday January 20, 2015

Financial news for SLXP dated on 2015-01-20: Report: Salix Pharmaceuticals Exploring Possible Sale

Financial news for SLXP dated on 2015-01-20: Shares of Salix Pharma Resume, Now Up Nearly 6%

Financial news for SLXP dated on 2015-01-20: Salix Working With Centerview Partners to Explore Options Including Sale, According to Sources -Reuters

Financial news for SLXP dated on 2015-01-20: Shares of Salix Pharma Halted on Circuit Breaker, Now Up 4+%

Financial news for SLXP dated on 2015-01-20: Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks

Financial news for SLXP dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for SLXP dated on 2015-01-08: Pharming, Salix Announce First Patient Treated In Clinical Study Of Ruconest

Financial news for SLXP dated on 2015-01-06: Cantor Fitzgerald Maintains Buy on Salix Pharmaceuticals, Raises PT to \$145.00

Financial news for SLXP dated on 2015-01-05: Salix Pharmaceuticals Announces Retirement Of CEO Carolyn Logan; Mr. D'Alonzo To Act As CEO

Financial news for SLXP dated on 2014-12-18: Benzinga's M&A Chatter for Thursday December 18, 2014

Financial news for SLXP dated on 2014-12-18: UPDATE: Some Salix Shareholders Pushing for Sale -Reuters

Financial news for SLXP dated on 2014-12-18: Paulson & Co Takes Stake in Salix -Reuters

Financial news for SLXP dated on 2014-12-18: Credit Suisse Raises Salix Pharmaceuticals Price Target

Financial news for SLXP dated on 2014-12-18: Credit Suisse Maintains Neutral on Salix Pharmaceuticals, Raises PT to \$121.00

Financial news for SLXP dated on 2014-12-16: #PreMarket Movers From December 16, 2014

Financial news for SLXP dated on 2014-12-16: Salix Pharmaceuticals, Ltd. Sees FY2016 EPS \$8.50-9.50, Sees Total Net Product Sales \$1.9-\$2B

Financial news for SLXP dated on 2014-12-16: Salix Pharmaceuticals, Ltd. Sees FY2015 EPS \$3.10-4.10

Financial news for SLXP dated on 2014-12-02: Sterne Agee Says Salix Pharmaceuticals Accounting Concerns Are 'Overdone'

Financial news for SLXP dated on 2014-11-20: Credit Suisse Maintains Neutral on Salix Pharmaceuticals, Ltd., Raises PT to \$111.00

Financial news for SLXP dated on 2014-11-14: How Adam Feuerstein Follows The Biotech Sector

Financial news for SLXP dated on 2014-11-10: Wedbush Reiterates Buy on Salix Pharmaceuticals, Ltd., Lowers PT to \$127.00

Financial news for SLXP dated on 2014-11-10: Deutsche Bank Slashes Price Target On Salix Pharmaceuticals

Financial news for SLXP dated on 2014-11-10: Breakfast Notes: Deutsche Markets Research Lowers PT on Salix Pharma., from \$134 to \$102 per share.

Financial news for SLXP dated on 2014-11-09: U.S. Produced Fewer Than Expected Jobs In October

Financial news for SLXP dated on 2014-11-07: Mid-Afternoon Market Update: Lions Gate Surges On Earnings Beat; Abercrombie & Fitch Shares Decline

Financial news for SLXP dated on 2014-11-07: Midday Losers From November 7: Roka Bioscience, Salix Pharmaceuticals, Intercept Pharmaceuticals, Extended Stay America

Financial news for SLXP dated on 2014-11-07: Mid-Day Market Update: Allscripts Healthcare Slides On Downbeat Earnings; Sears Shares Climb

Financial news for SLXP dated on 2014-11-07: Mid-Morning Market Update: Markets Edge Lower; Humana Profit Misses Estimates

Financial news for SLXP dated on 2014-11-07: Jefferies Sees Acquisition Of Salix Pharmaceuticals As Being Even More Likely Now

Financial news for SLXP dated on 2014-11-07: Morning Market Losers

Financial news for SLXP dated on 2014-11-07: Benzinga's Top Downgrades

Financial news for SLXP dated on 2014-11-07: Stifel Nicolaus Downgrades Salix Pharmaceuticals To Hold

Financial news for SLXP dated on 2014-11-07: Benzinga's Top #PreMarket Losers

Financial news for SLXP dated on 2014-11-07: UPDATE: Stifel Downgrades Salix Pharmaceuticals As Uncovered Inventories Leaves Many Open Questions

Financial news for SLXP dated on 2014-11-07: CORRECTION: Salix Pharmaceuticals Shares Down ~40% After Earnings Thursday Night

Financial news for SLXP dated on 2014-11-07: Jefferies Maintains Buy on Salix Pharmaceuticals, Ltd., Lowers PT to \$103.00

Financial news for SLXP dated on 2014-11-07: William Blair Downgrades Salix Pharmaceuticals, Ltd. to Market Perform, Lowers PT to \$89.00

Financial news for SLXP dated on 2014-11-07: Stifel Nicolaus Downgrades Salix Pharmaceuticals, Ltd. to Hold, Removes \$185.00 PT

Financial news for SLXP dated on 2014-11-06: Salix Shares Resume Trading, Now Down 40%

Financial news for SLXP dated on 2014-11-06: Salix Pharmaceuticals, Ltd. Sees Q4 ADJ. EPS \$1.16-1.95

Financial news for SLXP dated on 2014-11-06: Salix Pharmaceuticals Appoints Timothy Creech As CFO

Financial news for SLXP dated on 2014-11-06: Salix Pharmaceuticals, Ltd. Reports Q3 EPS of \$1.53 vs \$1.56 Est; Revenue of \$354.70M vs \$394.04M Est

Financial news for SLXP dated on 2014-11-06: Salix Pharma Shares Halted News Pending

Financial news for SLXP dated on 2014-11-06: Salix Pharma Shares Volatile, Slightly Lower as Bloomberg Reporting Co. Talks with Actavis Have Been Put on Hold

Financial news for SLXP dated on 2014-11-06: Earnings Scheduled For November 6, 2014

Financial news for SLXP dated on 2014-11-04: Pharming Group Confirms Receipt of \$20 Million Milestone Payment from Salix Pharmaceuticals as per Commercialization Agreement Between Salix and Pharming

Financial news for SLXP dated on 2014-10-21: Salix Reports TARGET 3 Study Showed 42% of Subjects Responded to Repeat Treatment with Rifaximin 550mg Based on Endpoint

Financial news for SLXP dated on 2014-10-16: Will Actavis Win Competition For Allergan's Affection?

Financial news for SLXP dated on 2014-10-09: Salix Pharma Spikes to High

Financial news for SLXP dated on 2014-10-07: Jefferies Reinstates Buy on Salix Pharmaceuticals, Ltd., Announces \$177.00 PT

Financial news for SLXP dated on 2014-10-06: Progenics Receives \$40M Milestone Following FDA Approval of RELISTOR For OIC Patients With Chronic Non-Cancer Pain

Financial news for SLXP dated on 2014-10-03: Unleash The Bulls: Surge In September Hiring Data Jolts Markets Higher

Financial news for SLXP dated on 2014-10-03: Credit Suisse Upgrades Salix Pharmaceuticals, Ltd. to Neutral

Financial news for SLXP dated on 2014-10-03: Salix Shares Rise 4.5% Premarket Following Announcement of Termination of Merger Agreement with Cosmo

Financial news for SLXP dated on 2014-10-03: Salix Pharmaceuticals, Cosmo Technologies Terminate Merger Agreement

Financial news for SLXP dated on 2014-10-02: Salix Pharma Spikes Higher; In Talks to Sell to Actavis -Bloomberg

Financial news for SLXP dated on 2014-10-02: Shares of Allergan, Salix Pharma Volatile as CNBC's David Faber Suggesting Talks Between Cos. Have 'Cooled'

Financial news for SLXP dated on 2014-10-02: CNBC's David Faber Reports Salix to Terminate Inversion Deal with Cosmo, According to Sources

Financial news for SLXP dated on 2014-10-01: Reuters Reports ISS Urges Allergan to Allow Shareholders to Vote on Any Large Deals, According to Sources

Financial news for SLXP dated on 2014-10-01: Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover

Financial news for SLXP dated on 2014-09-30: Morning Market Losers

Financial news for SLXP dated on 2014-09-29: Progenics Shares Resume Trading, Now Up 3.5%

Financial news for SLXP dated on 2014-09-29: UPDATE: Salix, Progenics Report FDA Okay of RELISTOR

Financial news for SLXP dated on 2014-09-29: Salix, Progenics Report FDA Okay of RELISTOR

Financial news for SLXP dated on 2014-09-28: Jackson Square Partners Joins Investors Opposing Allergan Bid for Salix

Financial news for SLXP dated on 2014-09-24: Benzinga's M&A Chatter for Wednesday September 24, 2014

Financial news for SLXP dated on 2014-09-24: CNBC's David Faber Says Actavis and Salix in Early Stage Discussions Regarding Potential Deal

Financial news for SLXP dated on 2014-09-24: #PreMarket Primer: Wednesday, September 24: US Economy Looking Strong In The Third Quarter

Financial news for SLXP dated on 2014-09-23: Benzinga's M&A Chatter for Tuesday September 23, 2014

Financial news for SLXP dated on 2014-09-23: Dow Finishes Down 100+ Points For Second Consecutive Day

Financial news for SLXP dated on 2014-09-23: Dow Down 0.6%; CarMax Shares Fall After Q2 Results

Financial news for SLXP dated on 2014-09-23: Ascena Retail Drops On Downbeat Earnings; CF Industries Shares Gain

Financial news for SLXP dated on 2014-09-23: Markets Mixed; Carnival Profit Tops Street View

Financial news for SLXP dated on 2014-09-23: Benzinga's Volume Movers

Financial news for SLXP dated on 2014-09-23: Stocks Hitting 52-Week Highs

Financial news for SLXP dated on 2014-09-23: Morning Market Movers

Financial news for SLXP dated on 2014-09-23: Benzinga's Top #PreMarket Gainers

Financial news for SLXP dated on 2014-09-23: Salix Shares Rise 9% Premarket on Report of Takeover Talks with Allergan

Financial news for SLXP dated on 2014-09-23: Pershing Square Sends Letter to Allergan Board Regarding Salix Deal; Threatens Suit Against Allergan is Deal Doesn't Require Board Vote -DJ

Financial news for SLXP dated on 2014-09-23: #PreMarket Primer: Tuesday, September 23: First Airstrikes In Syria Begin

Financial news for SLXP dated on 2014-09-23: US Stock Futures Fall Ahead Of Economic Data

Financial news for SLXP dated on 2014-09-23: Stocks To Watch For September 23, 2014

Financial news for SLXP dated on 2014-09-22: Salix Pharmaceuticals, Ltd. Set To Be Acquired By Allergan, Inc.

Financial news for SLXP dated on 2014-09-22: Benzinga's M&A Chatter for Monday September 22, 2014

Financial news for SLXP dated on 2014-09-22: Dow Jones Reports Allergan Rejected Takeover Bid from Actavis in August; Actavis Still Interested in Allergan Deal; Allergan in Talks to Acquire Salix, According to Sources

Financial news for SLXP dated on 2014-09-22: 8-K from Par Pharma Shows Settlement Deal with Salix Pharma, Co. Will Make Payment of \$100M to Escrow Account Within Five Days, Expecting \$91M Charge in Q3

Financial news for SLXP dated on 2014-09-18: Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN 550mg sNDA for Treatment of IBS with Diarrhea

Financial news for SLXP dated on 2014-09-18: Salix Secures Additional Intellectual Property Relating To Rifaximin

Financial news for SLXP dated on 2014-09-15: UCERIS 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA

Financial news for SLXP dated on 2014-09-12: Credit Suisse Sees Downside In Shares Of Salix Pharmaceuticals, Ltd.

Financial news for SLXP dated on 2014-09-12: Credit Suisse Initiates Coverage on Salix Pharmaceuticals, Ltd. at Underperform, Announces \$139.00 PT

Financial news for SLXP dated on 2014-09-12: Lupin, Salix Announce Exclusive Distributionagreement for Canada

Financial news for SLXP dated on 2014-09-02: Salix Pharma Issues Response to XIFAXAN 550mg CRL

Financial news for SLXP dated on 2014-08-21: UPDATE: Salix Shares Fall 2.5% Premarket Following Report Talks with Allergan have Stalled

Financial news for SLXP dated on 2014-08-20: Shares of Salix Tumble ~\$5 Following Word Talks with Allergan Have Stalled

Financial news for SLXP dated on 2014-08-20: Allergan Talks to Buy Salix 'Dormant,' Co. Exploring Options Other Than Salix - Bloomberg

Financial news for SLXP dated on 2014-08-19: Benzinga's M&A Chatter for Tuesday August 19, 2014

Financial news for SLXP dated on 2014-08-19: Dow Flirts With 19,000, S&P 500 Approaches 2,000 & NASDAQ Trading At 14-Year Highs

Financial news for SLXP dated on 2014-08-19: Allergan Declines Comment on Rumor of Potential Deal with Salix

Financial news for SLXP dated on 2014-08-19: JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

Financial news for SLXP dated on 2014-08-19: UPDATE: Valeant, Jazz Shares Move Higher on WSJ Report of Potential Allergan Deal for Salix

Financial news for SLXP dated on 2014-08-19: Dow Jones Reports Allergan Has Approached Salix Pharmaceuticals About Acquisition, According to Sources

Financial news for SLXP dated on 2014-08-19: Salix Pharma Spikes Higher

Financial news for SLXP dated on 2014-08-11: Salix Pharma Reports Topline Results for Microbiome, C&D for TARGET 3 Rifaximin IBS-D Treatment Study: No Evidence of Significant Effects on Pathogen Emergence, Cross Resistance

Financial news for SLXP dated on 2014-08-11: US Stock Futures Signal Higher Start On Wall Street

Financial news for SLXP dated on 2014-08-11: FDA Assigns September 29, 2014 PDUFA

Goal Date for RELISTOR Subcutaneous Injection sNDA

Financial news for SLXP dated on 2014-08-08: Salix Sinks In #PreMarket On Disappointing Outlook, Q2 Results

Financial news for SLXP dated on 2014-08-08: Sterne Agee Adjusts Estimates For Salix Pharmaceuticals

Financial news for SLXP dated on 2014-08-07: Salix Pharmaceuticals, Ltd. Reports Q2 EPS of \$1.59 vs \$1.70 Est; Revenue of \$382.0M vs \$396.82M Est, Cuts FY Guidance

Financial news for SLXP dated on 2014-08-07: Earnings Scheduled For August 7, 2014

Financial news for SLXP dated on 2014-08-06: Cantor Fitzgerald Upgrades Salix Pharmaceuticals, Ltd. to Buy, Raises PT to \$157.00

Financial news for SLXP dated on 2014-08-04: 5 Drug Companies Profiting From Generics

Financial news for SLXP dated on 2014-07-17: US Stock Futures Tumble Ahead Of Morgan Stanley Earnings

Financial news for SLXP dated on 2014-07-17: Salix, Pharming Announce FDA Approval of RUCONEST for Treatment of Acute Angioedema Attacks in Patients with HAE

Financial news for SLXP dated on 2014-07-14: Morning Market Movers

Financial news for SLXP dated on 2014-07-14: Benzinga's Top #PreMarket Gainers

Financial news for SLXP dated on 2014-07-14: US Stock Futures Surge; All Eyes On Citigroup Results

Financial news for SLXP dated on 2014-07-14: PREVIEW: Progenics Pharmaceuticals to Resume Trading at 7:30 AM ET

Financial news for SLXP dated on 2014-07-14: UPDATE: Salix, Progenics Report FDA Office Of Drug Evaluation III Approves Salix Request For FDA Approval Of RELISTOR sNDA

Financial news for SLXP dated on 2014-07-14: Progenics Announces Will Host Call Related to FDA Appeal Response Related to RELISTOR sNDA

Financial news for SLXP dated on 2014-07-14: Salix, Progenics Report FDA Office of Drug Evaluation III Approves Salix Request for FDA Approval of RELISTOR sNDA

Financial news for SLXP dated on 2014-07-09: Salix Pharmaceutical's Inversion Deal Makes It Unlikely Merger Target, Dilutes EPS

Financial news for SLXP dated on 2014-07-09: FOMC To End QE In October; The Container Store Shares Slide

Financial news for SLXP dated on 2014-07-09: AeroVironment Surges On Upbeat Results; The Container Store Shares Slide

Financial news for SLXP dated on 2014-07-09: Markets Edge Higher; Alcoa Profit Beats Street View

Financial news for SLXP dated on 2014-07-09: From Salix Pharma Call to Discuss Merger: Reaffirms FY14 Sales, EPS Outlook, Targeting Three to Five Year Gross Margin in 81-83% Range, EBITDA as Percent of Sales 45-50%

Financial news for SLXP dated on 2014-07-09: Morning Market Losers

Financial news for SLXP dated on 2014-07-08: Traders Sell Salix Pharma Shares Following Merger News

Financial news for SLXP dated on 2014-07-08: Shares of Salix Pharma Resume Trade, Now Up ~2%

Financial news for SLXP dated on 2014-07-08: Shares of Salix Pharma to Resume Trade at 5:30 p.m. EDT

Financial news for SLXP dated on 2014-07-08: UPDATE: Salix Pharma Halted Following Release of News Co. Will Combine with Cosmo Technologies

Financial news for SLXP dated on 2014-07-08: UPDATE: Upon Closing of Salix Pharma/Cosmo Merger, SLXP Holders Expected to Own Slightly Less Than 80% of Ordinary SLXP Shares

Financial news for SLXP dated on 2014-07-08: Salix Pharma Halted Following Release of

News Co. Will Combine with Cosmo Technologies

Financial news for SLXP dated on 2014-07-01: Dow Flirts With 17,000, S&P 500 Inches Closer To 2,000 In First Trading Day Of The Third Quarter

Financial news for SLXP dated on 2014-07-01: Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

Financial news for SLXP dated on 2014-07-01: Mid-Day Market Update: Acuity Brands Drops On Downbeat Results; GoPro Shares Surge

Financial news for SLXP dated on 2014-07-01: Mizuho Raises Price Target For Salix Pharmaceuticals

Financial news for SLXP dated on 2014-07-01: Benzinga's Volume Movers

Financial news for SLXP dated on 2014-07-01: Markets Surge; GM June Sales Rise 1%

Financial news for SLXP dated on 2014-07-01: Stocks Hitting 52-Week Highs

Financial news for SLXP dated on 2014-07-01: Morning Market Movers

Financial news for SLXP dated on 2014-07-01: Benzinga's Top #PreMarket Gainers

Financial news for SLXP dated on 2014-07-01: Salix Announces Endpoint Was Met in Study

Financial news for SLXP dated on 2014-06-27: Benzinga's Top Initiations

Financial news for SLXP dated on 2014-06-27: Canaccord Genuity Initiates Coverage on Salix Pharmaceuticals, Ltd. at Buy, Announces \$145.00 PT

Financial news for SLXP dated on 2014-06-13: UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On FDA Panel Outcome

Financial news for SLXP dated on 2014-06-12: Salix Pharma, Progenics Pharma Report on FDA Advisory Panel Recommendations, 12 Members Voted Not to Require CVOT Trial, Sseven Vote to Require CVOT for Pamorsa

Financial news for SLXP dated on 2014-06-12: Salix Pharmaceuticals Spikes Higher

Financial news for SLXP dated on 2014-06-12: UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ahead Of FDA Panel Vote

Financial news for SLXP dated on 2014-06-11: Wells Fargo Initiates Coverage On The Pharmaceutical Space

Financial news for SLXP dated on 2014-06-11: Wells Fargo Initiates Coverage on Salix Pharmaceuticals, Ltd. at Market Perform

Financial news for SLXP dated on 2014-06-09: Option Alert: Salix Pharmaceuticals July \$120/\$135 Call Spread; 2,000 Spread Trade; Currently \$111.77

Financial news for SLXP dated on 2014-05-27: UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On Upcoming Catalysts

Financial news for SLXP dated on 2014-05-13: Top 4 Mid-Cap Stocks In The Drugs-Generic Industry With The Highest ROA

Financial news for SLXP dated on 2014-05-08: Salix Pharmaceuticals, Ltd. Sees FY2014 EPS \$6.33 vs \$6.59 Est; Sees Sales \$1.60B vs \$1.62B Est

Financial news for SLXP dated on 2014-05-08: Salix Pharmaceuticals, Ltd. Sees Q2 EPS \$1.63 vs \$1.71 Est; Sees Sales \$395.0M vs \$393.39M Est

Financial news for SLXP dated on 2014-05-08: Salix Pharmaceuticals, Ltd. Reports Q1 EPS of \$1.05 vs \$0.91 Est; Revenue of \$384.40M vs \$372.94M Est

Financial news for SLXP dated on 2014-04-22: US Stock Futures Edge Higher Ahead Of McDonald's Earnings

Financial news for SLXP dated on 2014-04-22: Salix Pharma, Progenics Reports Acceptance of Submission for Expanded Use of RELISTOR in Chronic Non-Cancer Pain by EMA

Financial news for SLXP dated on 2014-04-22: Salix Pharmaceuticals, Progenics Pharmaceuticals Announce the Acceptance of Submission to Expand Use of RELISTORby the European Medicines Agency

Financial news for SLXP dated on 2014-04-21: Jefferies Initiates Coverage on Salix Pharmaceuticals, Ltd. at Buy, Announces \$133.00 PT

Financial news for SLXP dated on 2014-04-16: Sterne Agee Initiates Coverage on Salix Pharmaceuticals, Ltd. at Buy, Announces \$126.00 PT

Financial news for SLXP dated on 2014-02-28: Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr

Financial news for SLXP dated on 2014-02-27: Salix Pharmaceuticals, Ltd. Sees FY2014 EPS \$6.46

Financial news for SLXP dated on 2014-02-27: Salix Pharmaceuticals, Ltd. Sees Q1 EPS \$0.85

Financial news for SLXP dated on 2014-02-27: Salix Pharmaceuticals, Ltd. Reports Q4 EPS of \$1.06 vs \$0.93 Est; Revenue of \$257.60M vs \$247.29M Est

Financial news for SLXP dated on 2014-02-27: Salix Pharma, Redhill Biopharma Announces Worldwide Exclusive License Pact, Includes Upfront Payment \$7M, to Make Up to Added \$5M in Payments

Financial news for SLXP dated on 2014-02-25: UPDATE: Salix Wins Verdict Against Napo Pharmaceuticals

Financial news for SLXP dated on 2014-02-25: Salix Wins Napo Pharma Litigation on Fulyzaq

Financial news for SLXP dated on 2014-02-24: Pharming, Salix Announce Extension of PDUFA Action Date for Ruconest to July 16, 2014

Financial news for SLXP dated on 2014-02-21: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Financial news for SLXP dated on 2014-02-19: Hearing Buckingham Positive on Salix Pharmaceuticals

Financial news for SLXP dated on 2014-02-06: Option Alert: Progenics Mar \$6 Call; 3,078 Contracts Traded vs 697 OI; Currently \$4.55

Financial news for SLXP dated on 2014-02-06: Bloomberg Reporting Progenix, Salix Informed by FDA That ADPAC Meeting Postponed; FDA Cited Scheduling Conflicts

Financial news for SLXP dated on 2014-02-04: Salix Pharma Announces Issuance of US Patent for Rifaximin

Financial news for SLXP dated on 2014-01-13: Salix Pharma Issues Post-Merger Update, Sees FY14 Sales \$1.6B vs \$1.57B Est., Adj. EPS \$6.09 vs \$5.04 Est.

Financial news for SLXP dated on 2014-01-07: UPDATE: Bank of America Downgrades Salix Pharmaceuticals, Keeps PO

Financial news for SLXP dated on 2014-01-07: Bank of America Downgrades Salix Pharmaceuticals, Ltd. to Underperform

Financial news for SLXP dated on 2014-01-02: Salix Pharma Says 76.4% of Santarus Shares TEnded, All Conditions Have Been Satisfied

Financial news for SLXP dated on 2013-12-17: UPDATE: Stifel Upgrades Salix Pharmaceuticals Based on SNTS Deal Accretion

Financial news for SLXP dated on 2013-12-17: Stifel Nicolaus Upgrades Salix Pharmaceuticals, Ltd. to Buy, Announces \$108.00 undefined

Financial news for SLXP dated on 2013-12-16: Top 4 Stocks In The Drugs-Generic Industry With The Highest Operating Margin

Financial news for SLXP dated on 2013-12-13: Top 4 Stocks In The Drugs-Generic Industry With The Highest ROA

Financial news for SLXP dated on 2013-12-10: Salix Pharma Announces Expiration of HSR Waiting Period

Financial news for SLXP dated on 2013-12-03: Salix Commences Cash Tender Offer for Outstanding Shares of Santarus at \$32.00/Share

Financial news for SLXP dated on 2013-12-02: S&P Assigns B+ CCR on Salix Pharma; Outlook Stable

Financial news for SLXP dated on 2013-11-18: Salix Receives FDA CDRH Approval for Additional Injection Techniques for Deflux

Financial news for SLXP dated on 2013-11-08: Mid-Afternoon Market Update: RocketFuel Drops Following First Earnings Report, Markets Rise

Financial news for SLXP dated on 2013-11-08: Mid-Day Market Update: Nasdaq Rises 1.3%; Santarus Shares Surge On Salix Deal

Financial news for SLXP dated on 2013-11-08: Mid-Morning Market Update: Markets Rise; McDonald's October Comparable-Restaurant Sales Rise 0.5%

Financial news for SLXP dated on 2013-11-08: Stocks Hitting 52-Week Highs

Financial news for SLXP dated on 2013-11-08: Janney Capital Upgrades Salix Pharmaceuticals, Ltd. to Buy, Raises PT to \$95.00

Financial news for SLXP dated on 2013-11-08: Piper Jaffray Downgrades Santarus, Inc. to Neutral, Raises PT to \$32.00

Financial news for SLXP dated on 2013-11-07: Benzinga's M&A Chatter for Thursday November 7, 2013

Financial news for SLXP dated on 2013-11-07: Salix Pharmaceuticals, Ltd. Reports Q3 EPS of \$0.89 vs \$0.86 Est; Revenue of \$238.20M vs \$239.70M Est

Financial news for SLXP dated on 2013-11-07: Salix Pharm to Buy Santarus for \$2.6B

Financial news for SLXP dated on 2013-10-08: Top 4 Stocks In The Drugs-Generic Industry With The Highest Cash

Financial news for SLXP dated on 2013-10-01: Salix Says FDA Scheduled to Review Relistor SNDA March 10-11

Financial news for SLXP dated on 2013-09-17: Goldman Sachs Reinstates Neutral on Salix Pharmaceuticals, Ltd., Announces \$73.00 PT

Financial news for SLXP dated on 2013-09-09: Leerink Swann Upgrades Salix Pharmaceuticals, Ltd. to Outperform, Raises PT to \$80.00

Financial news for SLXP dated on 2013-08-09: BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials

Financial news for SLXP dated on 2013-08-08: Salix Pharmaceuticals, Ltd. Lowers FY2013 EPS Guidance from \$3.37 to \$3.20 vs \$3.47 Est

Financial news for SLXP dated on 2013-08-08: Salix Pharmaceuticals, Ltd. Reports Q2 EPS of \$0.87 vs \$0.81 Est; Revenue of \$235.40M

Financial news for SLXP dated on 2013-08-08: Earnings Scheduled For August 8, 2013

Financial news for SLXP dated on 2013-08-05: UPDATE: Cantor Fitzgerald Downgrades Salix Pharmaceuticals on Fair Valuation

Financial news for SLXP dated on 2013-08-05: Benzinga's Top Downgrades

Financial news for SLXP dated on 2013-08-05: Cantor Fitzgerald Downgrades Salix Pharmaceuticals, Ltd. to Hold, Raises PT to \$81.00

Financial news for SLXP dated on 2013-08-02: S&P: Heaping Praise For Some Health Care ETFs

Financial news for SLXP dated on 2013-07-26: Top 4 Stocks In The Drugs-Generic Industry With The Lowest PEG Ratio

Financial news for SLXP dated on 2013-07-23: Salix to be Added to S&P MidCap 400, Agree, DXP Enterprises to be Added to SmallCap 600

Financial news for SLXP dated on 2013-07-15: Don't Forget About This Small-Cap Health Care ETF

Financial news for SLXP dated on 2013-07-03: Bloomberg Reporting Optimer Said to Narrow Suitors to Cubist, Astellas, Salix

Financial news for SLXP dated on 2013-07-03: Bank of America Downgrades Salix Pharmaceuticals to Neutral

Financial news for SLXP dated on 2013-06-12: Buckingham Research Upgrades Salix Pharmaceuticals to Buy, Raises PT to \$90.00

Financial news for SLXP dated on 2013-06-11: Analyst Says News of FDA Panel for Salix's Relistor Could Provide 'Another Meaningful Catalyst'

Financial news for SLXP dated on 2013-06-11: Afternoon Market Gainers

Financial news for SLXP dated on 2013-06-11: Salix and Progenics Announce FDA Advisory Committee to Review Relistor sNDA for Opioid-Induced Constipation in Patients with Chronic Pain

Financial news for SLXP dated on 2013-05-30: Salix Pharma Buys Rights to Olon's IP Related to Amorphous Rifaximin

Financial news for SLXP dated on 2013-05-30: Salix Pharmaceuticals Acquires Patent from Olon Relating to Amorphous Rifaximin

Financial news for SLXP dated on 2013-05-28: UPDATE: Jefferies Raises PT on Salix Pharmaceuticals on Street Estimates Upside

Financial news for SLXP dated on 2013-05-28: Jefferies Maintains Buy on Salix Pharmaceuticals, Ltd., Raises PT to \$70.00

Financial news for SLXP dated on 2013-05-22: Salix Pharma Says Results for Budesonide Foam Statistically Significant

Financial news for SLXP dated on 2013-05-10: Janney Capital Downgraded Salix Pharmaceuticals, Ltd. to Neutral

Financial news for SLXP dated on 2013-05-09: Salix Pharmaceuticals, Ltd. Reports Q1 EPS of \$0.63 vs \$0.68 Est; Revenue of \$202.60M vs \$205.94M Est

Financial news for SLXP dated on 2013-03-21: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash

Financial news for SLXP dated on 2013-03-15: Top 4 Stocks In The Drugs-Generic Industry With The Highest Profit Margin

Financial news for SLXP dated on 2013-03-13: UPDATE: Bank of America Raises PT on Salix Pharmaceuticals on Sales Estimates

Financial news for SLXP dated on 2013-03-13: UPDATE: Bank of America Raises PT on Salix Pharmaceuticals on Pipeline Credit

Financial news for SLXP dated on 2013-03-13: Bank of America Maintains Buy on Salix Pharmaceuticals, Ltd., Raises PO to \$56.00

Financial news for SLXP dated on 2013-03-01: UPDATE: Cantor Fitzgerald Raises PT on Salix Pharmaceuticals on In-Line 4Q12 Results

Financial news for SLXP dated on 2013-02-28: If The Market Falls, Try These Low Beta ETFs

Financial news for SLXP dated on 2013-02-28: Salix Pharmaceuticals, Ltd. Reports Q4 EPS of \$0.81 vs \$0.79 Est; Revenue of \$198.20M vs \$199.62M Est

Financial news for SLXP dated on 2013-02-12: Salix Pharma Receives Subpoena Related to Xifaxan, Apriso, Relistor

Financial news for SLXP dated on 2013-01-31: Benzinga's Top Initiations

Financial news for SLXP dated on 2013-01-30: Janney Capital Initiates Coverage on Salix Pharmaceuticals, Ltd. at Buy, Announces \$55.00 PT

Financial news for SLXP dated on 2013-01-25: Salx Pharmaceuticals Spikes Higher

Financial news for SLXP dated on 2013-01-11: RBC Capital Initiates Coverage on Salix Pharmaceuticals, Ltd. at Outperform

Financial news for SLXP dated on 2013-01-07: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash

Financial news for SLXP dated on 2013-01-02: Cantor Fitzgerald Reiterates Buy Rating, \$60 PT on Salix Pharmaceuticals Ltd.

Financial news for SLXP dated on 2013-01-02: US Stock Futures Higher On Fiscal-Cliff Deal

Financial news for SLXP dated on 2013-01-02: FDA Approves Fulyzaq 125 mg Delayed-Release Tablets for Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral

Therapy

Financial news for SLXP dated on 2013-01-02: Stocks To Watch For January 2, 2013

Financial news for SLXP dated on 2012-11-30: Benzinga's Top Initiations

Financial news for SLXP dated on 2012-11-29: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest ROE

Financial news for SLXP dated on 2012-11-07: Salix Pharma Raises FY EPS Guidance from \$2.86 to \$3.13 vs \$2.87 Est, Sales Reaffirmed

Financial news for SLXP dated on 2012-11-07: Salix Pharmaceuticals Reports Q3 EPS \$0.26 May Not Compare to \$0.70 Est; Revenues \$137.9M vs \$187.63M Est

Financial news for SLXP dated on 2012-09-10: Leerink Swann Initiates Coverage on Salix Pharmaceuticals at Market Perform

Financial news for SLXP dated on 2012-09-05: Salix Pharma Will Give 5 Presentations at PAINWeek

Financial news for SLXP dated on 2012-08-09: Goldman Sachs Maintains Salix Pharmaceuticals at Neutral, Raises PT from \$47 to \$49

Financial news for SLXP dated on 2012-08-09: Benzinga's Top Upgrades

Financial news for SLXP dated on 2012-08-09: Piper Jaffray Maintains Salix Pharmaceuticals at Overweight, Lowers PT from \$57 to \$55

Financial news for SLXP dated on 2012-08-09: Cantor Fitzgerald Upgrades Salix Pharmaceuticals from Hold to Buy, Raises PT from \$59 to \$60

Financial news for SLXP dated on 2012-08-09: Jefferies & Company Maintains Salix Pharmaceuticals at Buy, Lowers PT from \$63 to \$58

Financial news for SLXP dated on 2012-08-08: Salix Pharma Guides Q3 EPS \$0.69 vs \$0.68; Guides Q3 Revenue \$185 vs \$189.9M Est

Financial news for SLXP dated on 2012-08-08: Salix Pharmaceuticals Reports Q2 EPS \$0.79 vs \$0.55 Est; Revenues \$181M vs \$180.79M Est

Financial news for SLXP dated on 2012-08-07: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue

Financial news for SLXP dated on 2012-08-06: Salix Pharmaceuticals Gets Paragraph IV for Mesalamine (Apriso)

Financial news for SLXP dated on 2012-07-30: Bank of America Maintains Salix Pharmaceuticals at Buy, Lowers PO from \$60 to \$58

Financial news for SLXP dated on 2012-07-30: Benzinga's Top Pre-Market Losers

Financial news for SLXP dated on 2012-07-30: ThinkEquity Downgrades Salix Pharmaceuticals from Buy to Hold

Financial news for SLXP dated on 2012-07-30: Susquehanna Downgrades Salix Pharmaceuticals from Positive to Neutral

Financial news for SLXP dated on 2012-07-30: Financial Breakfast: Morning News Summary for July 30, 2012

Financial news for SLXP dated on 2012-07-30: Salix Pharmaceuticals Falls 15%, Progenics Falls 40% Pre-Market Following Receipt of CRL from FDA

Financial news for SLXP dated on 2012-07-30: Friday, Salix and Progenics Receive Complete Response Letter from FDA for RELISTOR(R) sNDA; FDA Requests More Data

Financial news for SLXP dated on 2012-07-25: Put Spread Purchased in Salix Pharmaceuticals Ahead of FDA Decision/Q2 Earnings

Financial news for SLXP dated on 2012-07-25: Option Alert: Salix Pharmaceuticals Put Volume at 1,780% of Average; Currently \$50.44

Financial news for SLXP dated on 2012-07-18: Biotechs With Upcoming PDUFA Dates

Financial news for SLXP dated on 2012-07-05: Small-Cap Corner: A Forgotten Biotech ETF

Financial news for SLXP dated on 2012-07-03: UBS Maintains Salix Pharmaceuticals at

Neutral, Raises PT from \$54 to \$56

Financial news for SLXP dated on 2012-06-21: Option Alert: Salix Pharmaceuticals Call Volume at 1,688% of Average; Currently \$52.68

Financial news for SLXP dated on 2012-05-21: The Definitive Biotech ETF Guide (IBB, XBI, FBT)

Financial news for SLXP dated on 2012-05-15: Top 10 Small Cap ETFs

Financial news for SLXP dated on 2012-05-08: UPDATE: Goldman Sachs Raises Salix Pharmaceuticals' PT

Financial news for SLXP dated on 2012-05-08: UPDATE: Cantor Fitzgerald Raises Salix Pharmaceuticals' PT

Financial news for SLXP dated on 2012-05-08: UPDATE: Jefferies Raises PT to \$63 on Salix Pharmaceuticals; Q1 Beat and Raised Guidance

Financial news for SLXP dated on 2012-05-08: Cantor Fitzgerald Maintains Salix Pharmaceuticals at Buy, Raises PT from \$60 to \$61

Financial news for SLXP dated on 2012-05-08: Goldman Sachs Maintains Salix Pharmaceuticals at Neutral, Raises PT from \$43 to \$48

Financial news for SLXP dated on 2012-05-08: Jefferies & Company Maintains Salix Pharmaceuticals at Buy, Raises PT from \$54 to \$63

Financial news for SLXP dated on 2012-05-07: Salix Pharmaceuticals Reports Q1 EPS \$0.67 vs \$0.57 Est; Revenues \$171.1M vs \$168.29M Est

Financial news for SLXP dated on 2012-05-04: Earnings Preview: Salix's Q1 Earnings Expected to Soar 68% - IBD

Financial news for SLXP dated on 2012-04-30: Salix Pharmaceuticals Announces Extension of Crofelemer NDA Priority Review

Financial news for SLXP dated on 2012-04-10: UBS Maintains Salix Pharmaceuticals at Neutral, Raises PT from \$50 to \$54

Financial news for SLXP dated on 2012-04-10: Hearing Wells Fargo Defending Salix Pharmaceuticals

Financial news for SLXP dated on 2012-03-29: Top 4 Mid-Cap Stocks In The Drugs-Generic Industry With The Highest EPS

Financial news for SLXP dated on 2012-03-27: Hearing Salix Pharmaceuticals Downgraded from Buy to Neutral at Buckingham

Financial news for SLXP dated on 2012-03-15: Salix Pharmaceuticals Trading 1.6% Higher on Heavy Volume; Currently at \$51.82

Financial news for SLXP dated on 2012-03-13: Salix Pharmaceuticals Prices Convertible Notes Offering

Financial news for SLXP dated on 2012-03-12: Salix Pharmaceuticals Announces Proposed Convertible Notes Offering

Financial news for SLXP dated on 2012-03-12: Piper Jaffray: Crofelemer Expected to Show Clear Benefit Over Placebo

Financial news for SLXP dated on 2012-02-28: UPDATE: Jefferies Raises Price Target on Salix Pharmaceuticals to \$54

Financial news for SLXP dated on 2012-02-28: UPDATE: Auriga Upgrades Salix Pharmaceuticals to Buy

Financial news for SLXP dated on 2012-02-28: UPDATE: Piper Jaffray Reiterates Overweight, \$57 Target on Salix Pharmaceuticals

Financial news for SLXP dated on 2012-02-28: Cantor Fitzgerald: Salix Pharmaceuticals' Guidance Anticipates Significant Spending

Financial news for SLXP dated on 2012-02-28: Goldman Sachs Maintains Salix Pharmaceuticals at Neutral, Lowers PT from \$46 to \$43

Financial news for SLXP dated on 2012-02-28: Jefferies & Company Maintains Salix Pharmaceuticals at Buy, Raises PT from \$50 to \$54

Financial news for SLXP dated on 2012-02-28: Benzinga's Top Upgrades

Financial news for SLXP dated on 2012-02-28: Financial Breakfast: Morning News Summary for February 28, 2012

Financial news for SLXP dated on 2012-02-28: Auriga Upgrades Salix Pharmaceuticals from Hold to Buy, Announces PT of \$54

Financial news for SLXP dated on 2012-02-28: Auriga Upgrades Salix Pharmaceuticals from Hold to Buy, Announces PT of \$55

Financial news for SLXP dated on 2012-02-27: Salix Pharmaceuticals Reports Q4 Revenues \$155.20M vs \$152.60M Est

Financial news for SLXP dated on 2012-02-13: Brean Murray Carret: Nearer Term Positive Catalysts Understated for Salix Pharmaceuticals

Financial news for SLXP dated on 2012-02-10: Bank of America Sees Buying Opportunity on Salix's Weakness

Financial news for SLXP dated on 2012-02-06: Salix Pharma Wins FDA Approval for Balsalazide Sodium Tablets

Financial news for SLXP dated on 2012-02-06: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Operating Margin

Financial news for SLXP dated on 2012-01-23: Piper Jaffray Reinforces Bullish Thesis for Salix Pharmaceuticals

Financial news for SLXP dated on 2012-01-20: UPDATE: Stifel Nicolaus Downgrades Salix Pharmaceuticals to Hold

Financial news for SLXP dated on 2012-01-20: Stifel Nicolaus Downgrades SLXP, SONO, WBS to Hold

Financial news for SLXP dated on 2012-01-04: UPDATE: Piper Jaffray Raises Price Target on Salix Pharmaceuticals to \$57

Financial news for SLXP dated on 2012-01-04: Piper Jaffray Raises PT on Salix Pharmaceuticals to \$57

Financial news for SLXP dated on 2011-12-30: ETF Showdown: Fun With Pharma

Financial news for SLXP dated on 2011-12-23: UPDATE: Goldman Sachs Raises Price Target on Salix Pharmaceuticals to \$46

Financial news for SLXP dated on 2011-12-23: Goldman Sachs Raises PT on Salix Pharmaceuticals to \$46

Financial news for SLXP dated on 2011-12-22: Top 4 Stocks In The Drugs-Generic Industry With The Highest Profit Margin

Financial news for SLXP dated on 2011-12-20: Progenics Pharma Up 30% on Positive Phase 3 Results

Financial news for SLXP dated on 2011-12-20: Bank of America Raises PO on Salix Pharmaceuticals to \$55

Financial news for SLXP dated on 2011-12-20: Jefferies Raises PT on Salix Pharmaceuticals to \$50

Financial news for SLXP dated on 2011-12-20: Morning Market Movers

Financial news for SLXP dated on 2011-12-20: Financial Breakfast: Morning News Summary for December 20, 2011

Financial news for SLXP dated on 2011-12-20: Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic

Financial news for SLXP dated on 2011-12-14: Salix Submits New NDA, Investors Hope for New Stock Price Runs

Financial news for SLXP dated on 2011-12-14: Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea

Financial news for SLXP dated on 2011-12-09: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash

Financial news for SLXP dated on 2011-11-30: Investors Ideas: Tuesday's NASDAQ Winners

Financial news for SLXP dated on 2011-11-17: Piper Jaffray Maintains Overweight, \$51 Target on Salix Pharmaceuticals

Financial news for SLXP dated on 2011-11-16: Salix Pharmaceuticals Halted; Pending News

Financial news for SLXP dated on 2011-11-14: UPDATE: John Paulson & Co Dumped Stake in Lubrizol, SVVS, JP Morgan, NYSE Euronext, State Street, Teradata Corp, First Horizon National, SLXP, NeTApp, Northern Trust, Quest Software, and Bucyrus and BMC Software in Q3

Financial news for SLXP dated on 2011-11-14: Jefferies Maintains Buy Rating and \$42 PT on Salix Pharmaceuticals

Financial news for SLXP dated on 2011-11-10: UPDATE: Auriga Raises PT to \$34 on Salix Pharmaceuticals

Financial news for SLXP dated on 2011-11-09: Italy Starts to Make Greece Look Good 11-09-2011

Financial news for SLXP dated on 2011-11-09: Notable Put Options Activity in Salix Pharmaceuticals

Financial news for SLXP dated on 2011-11-09: Goldman Sachs Raises PT on Salix Pharmaceuticals to \$35

Financial news for SLXP dated on 2011-11-09: Brean Murray Carret & Co Maintains Buy Rating and \$50 PT on Salix Pharmaceuticals

Financial news for SLXP dated on 2011-11-09: Piper Jaffray Raises Price Target on Salix Pharmaceuticals to \$51

Financial news for SLXP dated on 2011-11-09: Piper Jaffray Raises PT on Salix Pharmaceuticals to \$51

Financial news for SLXP dated on 2011-11-08: End-of-Day Market Summary for November 8, 2011

Financial news for SLXP dated on 2011-11-08: Salix Pharma Reports Q3 EPS \$0.77 vs \$0.63 Est; Revenues \$146.2M vs \$139.95M Est

Financial news for SLXP dated on 2011-11-08: Salix Pharmaceuticals to Acquire Oceana Therapeutics for \$300M Cash

Financial news for SLXP dated on 2011-10-20: Salix Pharma Spiking Higher on Heavy Volume

Financial news for SLXP dated on 2011-10-04: Piper Jaffray Reiterates Overweight on Salix Pharmaceuticals

Financial news for SLXP dated on 2011-10-03: Bank of America Initiates Salix Pharmaceuticals at Buy, \$38 PO

Financial news for SLXP dated on 2011-09-13: Piper Jaffray Overweight On Salix Pharmaceuticals

Financial news for SLXP dated on 2011-09-06: Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Operating Margin

Financial news for SLXP dated on 2011-08-30: Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR in Patients with Non-Cancer Pain

Financial news for SLXP dated on 2011-08-24: Piper Jaffray Comments on Salix Pharmaceuticals

Financial news for SLXP dated on 2011-08-09: UPDATE: Piper Jaffray Raises PT on Salix Pharmaceuticals from \$47 to \$50

Financial news for SLXP dated on 2011-08-09: Piper Jaffray Raises PT on Salix Pharmaceuticals To \$50

Financial news for SLXP dated on 2011-08-08: Salix Pharmaceuticals Reports Q2 EPS \$0.54 vs \$0.48 Est; Revenues \$133.2M vs \$131.52M Est

Financial news for SLXP dated on 2011-07-20: Piper Jaffray Reiterates Overweight on SLXP

Financial news for SLXP dated on 2011-07-05: UPDATE: Duncan-Williams Color on Salix Pharmaceuticals Upgrade

Financial news for SLXP dated on 2011-07-05: Benzinga's Top Upgrades

Financial news for SLXP dated on 2011-07-05: Duncan Williams Upgrades Salix Pharmaceuticals To Buy, \$47 PT

Financial news for SLXP dated on 2011-06-21: Options Brief: Salix Pharmaceuticals, Ltd.

Financial news for SLXP dated on 2011-06-20: Piper Jaffray Reiterates Overweight Rating On Salix Pharmaceuticals

Financial news for SLXP dated on 2011-05-23: Piper Jaffray Overweight On Salix Pharmaceuticals

Financial news for SLXP dated on 2011-05-20: Salix Expects to Submit SNDA for Indication in Mid-2011

Financial news for SLXP dated on 2011-05-12: Duncan-Williams Maintains Buy Rating On Salix

Financial news for SLXP dated on 2011-05-10: Market updates- BG Group, Celanese, InterContinental Hotels, Imperial Tobacco, Schroders, CE, IHG, IMT, SDR, BG, VRTX, SLXP

Financial news for SLXP dated on 2011-05-09: A Peek Into The Market Before The Trading Starts

Financial news for SLXP dated on 2011-05-09: Salix Pharmaceuticals Receives Lawsuit from Napo Pharmaceuticals

Financial news for SLXP dated on 2011-05-05: Salix Pharma Reports Q1 EPS of \$0.34 vs. \$0.18 Estimate; Revenues \$105.9M vs. \$107.9M Estimate (SLXP)

Financial news for SLXP dated on 2011-04-21: UPDATE: Piper Jaffray Color On SLXP Target Increase

Financial news for SLXP dated on 2011-04-21: Piper Jaffray Raises PT on Salix Pharmaceuticals To \$42

Financial news for SLXP dated on 2011-04-15: Piper Jaffray Reports Salix Pharmaceuticals Not Alarmed By NEJM Letters

Financial news for SLXP dated on 2011-04-13: Jefferies Maintains Buy on Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-03-21: Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Highest Cash (SLXP, PRX, CPD, HITK)

Financial news for SLXP dated on 2011-03-11: Wells Fargo Ups SLXP To Outperform

Financial news for SLXP dated on 2011-03-01: Piper Jaffray Comments On Salix Pharmaceuticals Following Recent Earnings Report

Financial news for SLXP dated on 2011-03-01: Goldman Discusses Salix Pharmaceuticals, Ltd. (SLXP)

Financial news for SLXP dated on 2011-03-01: Oppenheimer Has Outperform On Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-02-28: Salix Pharmaceuticals Reports Q4 EPS of \$0.40 vs. \$0.49

Financial news for SLXP dated on 2011-02-25: UPDATE: Piper Jaffray Color On SLXP PT Decrease

Financial news for SLXP dated on 2011-02-25: Piper Jaffray Lowers PT On Salix Pharmaceuticals To \$39

Financial news for SLXP dated on 2011-02-24: Fast Money Pops & Drops, February 24th (OCR, PCLN, MU, SLXP, NEM)

Financial news for SLXP dated on 2011-02-24: Leaving on a Jet Plane, Will the Market Come Back Again? 02-24-2011

Financial news for SLXP dated on 2011-02-24: Benzinga's Top Pre-Market NASDAQ Losers

(SLXP, AXTI, IDCC, CLMT)

Financial news for SLXP dated on 2011-02-17: Goldman Sachs Maintains Buy on Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-02-17: Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash (MYL, SLXP, HITK, AKRX)

Financial news for SLXP dated on 2011-02-15: Piper Jaffray Reiterates Overweight on Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-02-08: Piper Jaffray Reiterates OW Rating, \$60 PT On SLXP

Financial news for SLXP dated on 2011-02-07: Benzinga's Top Pre-Market NASDAQ Gainers (OREX, PGNX, GOLD, GENZ)

Financial news for SLXP dated on 2011-02-01: Options Brief: Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-01-28: Stocks Battle Back 01-25-2011

Financial news for SLXP dated on 2011-01-28: Puts Purchased on Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-01-25: Tuesday's Put/Call Ratio Leaders (EMS, CMED, NWSA, DHR, SLXP)

Financial news for SLXP dated on 2011-01-25: Options Brief: Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2011-01-12: Salix Pharmaceuticals, Inc. and the Colon Cancer Alliance Announce Colonoscopy For Dummies(r) is Now Available for Free Download

Financial news for SLXP dated on 2011-01-05: XIFAXAN 550 mg Tablets Demonstrated Significant Acute and Sustained Relief of Irritable Bowel Syndrome Without Constipation

Financial news for SLXP dated on 2011-01-04: Tuesday's Put/Call Ratio Leaders (SLXP, NWSA, CYH, RDC, MUR)

Financial news for SLXP dated on 2011-01-04: Puts Purchased on Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2010-12-21: Piper Jaffray Reiterates Overweight Rating on Salix Pharma (SLXP)

Financial news for SLXP dated on 2010-12-13: Options Brief: Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2010-12-03: Salix Stays Neutral - Analyst Blog

Financial news for SLXP dated on 2010-12-03: Salix Stays Neutral - Analyst Blog

Financial news for SLXP dated on 2010-12-02: Goldman Reiterates Its Buy On Salix Pharmaceuticals Post Mgmt. Meeting

Financial news for SLXP dated on 2010-12-01: Salix Bullish on Xifaxin (SLXP)

Financial news for SLXP dated on 2010-11-29: Capstone Investments Initiates SLXP With Buy

Financial news for SLXP dated on 2010-11-22: Company News for November 22, 2010 - Corporate Summary

Financial news for SLXP dated on 2010-11-22: Goldman Initiating Coverage On Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2010-11-22: Goldman Sachs Initiates Coverage on Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2010-11-22: Company News for November 22, 2010 - Corporate Summary

Financial news for SLXP dated on 2010-11-15: Xifaxan Drives Salix - Analyst Blog

Financial news for SLXP dated on 2010-11-11: Benzinga's Top Performing Industries (CTRP, INTX, FCX, SCCO, NYT, GCI, WPO, SSRI, HL, SLXP, TBV)

Financial news for SLXP dated on 2010-11-08: Salix Pharmaceuticals Reports 3Q2010 Results: Loss Per Share of \$0.05

Financial news for SLXP dated on 2010-10-27: Salix Inks Deal - Analyst Blog

Financial news for SLXP dated on 2010-10-06: Salix Drug Approval Date Pushed Out - Analyst Blog

Financial news for SLXP dated on 2010-10-04: Piper Jaffray's Specialty Pharma Update (SLXP, FRX, SHPGY)

Financial news for SLXP dated on 2010-10-01: Piper Jaffray Tidbits From Salix Management

Financial news for SLXP dated on 2010-09-30: Salix Pharmaceuticals Initiated At Neutral

Financial news for SLXP dated on 2010-09-23: Salix Pharma CEO Sells 14,000 Shares of SLXP

Financial news for SLXP dated on 2010-09-21: Salix Expecting \$1B In Sales For Xifaxan

Financial news for SLXP dated on 2010-09-03: Salix Settles MoviPrep Lawsuit - Analyst Blog

Financial news for SLXP dated on 2010-08-23: Favorable Update From Salix Pharmaceuticals

Financial news for SLXP dated on 2010-08-11: Benzinga's Top ETF Gainers (DPK, SOXS, TZA, FAZ)

Financial news for SLXP dated on 2010-08-11: Xifaxan Boosts Salix Earnings - Analyst Blog

Financial news for SLXP dated on 2010-08-10: Piper Jaffray Overweight On Salix Pharmaceuticals, Has \$58 Target (SLXP)

Financial news for SLXP dated on 2010-08-09: Salix Pharmaceuticals Ltd. (SLXP) Tops Estimates; Guides Lower

Financial news for SLXP dated on 2010-07-29: Top 4 Stocks In The Drug Related Products With The Highest Free Cash Flow (HLF, NTY, PRGO, SLXP)

Financial news for SLXP dated on 2010-07-23: Piper Jaffray Reiterates Overweight, \$58 Price Target On Salix Pharmaceuticals (SLXP)

Financial news for SLXP dated on 2010-07-21: Jeffries Reiterates BUY Rating on SLXP

Financial news for SLXP dated on 2010-07-13: Salix Pharmaceuticals (SLXP) Gets Overweight From Piper Jaffray

Financial news for SLXP dated on 2010-06-30: Pharmaceutical ETFs on the Rise

Financial news for SLXP dated on 2010-06-07: Piper Jaffray Reiterates Overweight Rating on Salix Pharma (SLXP)

Financial news for SLXP dated on 2010-06-02: Piper Jaffray Maintains Overweight Rating On Salix Pharmaceuticals, Ltd. (SLXP)

Financial news for SLXP dated on 2010-05-11: SLXP Posts Strong Q1 Results With Higher Xifaxan 200 Sales

Financial news for SLXP dated on 2010-04-08: PowerShares Small Cap Sector ETFs Hit the Tape

Financial news for SLXP dated on 2010-04-06: Chances of Approval Of SLXP's Xifaxan Improve

Financial news for SLXP dated on 2010-03-25: SLXP - Salix Pharmaceuticals Ltd. Gets FDA Approval For XIFAXAN(r)

Financial news for SLXP dated on 2010-03-25: Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating

Financial news for SLXP dated on 2010-03-25: FDA Approves SLXP's Xifaxan

Financial news for SLXP dated on 2010-03-25: Benzinga's Top Pre-Market Gainers (CIGX, SLXP, GIII, SCLN)

Financial news for SLXP dated on 2010-03-25: U.S. Equity Market Preview (CAT, CEPH, FSLR, ESLR, ENER)

Financial news for SLXP dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for SLXP dated on 2010-03-10: Optimistic Future for Salix Pharmaceuticals Ltd. (SLXP)

Financial news for SLXP dated on 2010-03-10: Oppenheimer Maintains Salix Pharmaceuticals (SLXP) Outperform Rating

Financial news for SLXP dated on 2010-03-10: Benzinga's Top Pre-Market Losers (PSS, NAV, AVAV, RMIX, SLXP)

Financial news for SLXP dated on 2010-02-24: Top Performing Industries For February 24 (RCL, MU, ADSK, SLXP, LOW)

Financial news for SLXP dated on 2010-02-24: Benzinga's Volume Movers (SLXP, DLTR, PZZA, ADSK, BCSI)

Financial news for SLXP dated on 2010-02-24: Salix Pharmaceuticals Ltd (SLXP) Breaches 20 Day MA And 50 Day MA After Gap-Up Opening

Financial news for SLXP dated on 2010-02-24: Salix Pharmaceuticals (SLXP) Shares Up Nearly 20%

Financial news for SLXP dated on 2010-02-24: Benzinga's Top Pre-Market Gainers (ZLC, ADSK, GLDD, SLXP, ARNA)

Financial news for SLXP dated on 2010-02-23: Salix Pharma Shoots Higher In After Hours (SLXP)

Financial news for SLXP dated on 2010-02-22: Benzinga's Volume Movers (GPRE, CAGC, SLB)

Financial news for SLXP dated on 2010-02-19: Salix Pharma. Drops In Premarket (SLXP)

Financial news for SLXP dated on 2010-02-19: Benzinga's Top Pre-Market Losers (CSIQ, APOL, LOPE, SLXP)

Financial news for SLXP dated on 2010-02-01: SLXP Gets "Buy" Rating

Financial news for SLXP dated on 2010-01-05: Benzinga's Volume Movers (SLXP, CAAS, WPRT, TKTM, HRBN)

Financial news for SLXP dated on 2010-01-05: Benzinga's Top Pre- Market Gainers (QCOM, CRTP, PALM, POT, SLXP, APWR, STEC)

Financial news for SLXP dated on 2009-10-01: New 52-Week High Stocks (APT,DEPO,DISCA,NETC,SLXP)

Financial news for SLXP dated on 2009-09-14: New 52-Week High Stocks -SLXP,TA,ZOOM,CHTP,MOT

Financial news for SLXP dated on 2009-09-14: SLXP Climbs 52% To New 52-Week high as it's drug Rifaximin met the main goal of late-stage studies